ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at ben.rubin@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
07/31/201516:37:00Gilead Sciences annonce ses résultats financiers pour le deuxième t...
07/31/201512:15:00Gilead Sciences gibt Finanzergebnisse für zweites Quartal 2015...
07/31/201511:37:00Gilead Sciences annuncia i risultati finanziari registrati nel...
07/28/201520:11:00Gilead Sciences gibt Dividenden für Drittes Quartal 2015 bekannt
07/28/201520:06:00Gilead Sciences annonce son dividende du troisième trimestre...
07/28/201517:30:04Express Scripts Raises Guidance as Earnings Top Views
07/28/201517:19:14Express Scripts Raises Guidance as Earnings Top Views
07/28/201517:00:35Gilead Sales Soar on Hepatitis Drugs
07/28/201516:52:47Gilead Sales Soar on Hepatitis Drugs
07/28/201516:04:26Current Report Filing (8-k)
07/28/201516:02:00Gilead Sciences Announces Third Quarter 2015 Dividend
07/28/201516:02:00Gilead Sciences annuncia il dividendo del terzo trimestre del...
07/28/201516:01:00Gilead Sciences Announces Second Quarter 2015 Financial Results
07/28/201502:53:00Gilead annuncia alcune promozioni
07/28/201501:52:00Gilead annonce la promotion de cadres de direction
07/28/201501:45:00Gilead gibt Beförderungen im Führungspersonal bekannt
07/27/201516:30:00Gilead Announces Executive Promotions
07/24/201515:00:06FDA Approves Cholesterol Drug From Regeneron, Sanofi
07/23/201508:38:00Gilead annonce les résultats de phase 3 de la première étude vis...
07/23/201507:23:00Gilead berichtet Ergebnisse aus Phase III der ersten Studie...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad